Efficacy of Huayu Xiaozheng decoction combined with triptorelin and mifepristone in the treatment of uterine fibroids and its effect on uterine artery hemodynamics.
Zhou. Yuru Y; Liu. Xinyuan X; Yang. Xiaotian X; Yu. Yaxin Y; Zhou. Yue Y; Zhou. Huifang H
Key Findings
- The triple combo gave a higher overall effective rate than drugs alone (p<0.05).
- Fibroid size, menstrual flow, and hormone levels dropped more in the combo group (p<0.05).
- Uterine artery blood‑flow indices (PI, RI, S/D) improved more with the herbal addition (p<0.05).
- Adverse‑reaction rate was lower with the herbal mix (p=0.013).
- Recurrence after one year was numerically lower but not statistically significant (7.8% vs 11.8%).
Practical Outcomes
- For biohackers who have uterine fibroids, pairing triptorelin and mifepristone with Huayu Xiaozheng decoction may boost efficacy and cut side‑effects, but the benefit is modest and specific to this condition. It isn’t a general longevity or performance protocol, and the herbal formula’s exact composition isn’t detailed, so replication may be challenging.
Summary
Adding the Chinese herbal mix Huayu Xiaozheng decoction to the standard drugs triptorelin and mifepristone helped women with uterine fibroids shrink their tumors a bit more, improve blood flow in the uterus, and experience fewer side‑effects, though the drop in fibroid comeback after a year wasn’t statistically clear.
Abstract
To expound the efficacy of Huayu Xiaozheng Decoction (HYXZD) combined with triptorelin and mifepristone in the treatment of uterine fibroids, with a particular focus on its effect on uterine artery hemodynamics. A total of 102 women with uterine fibroids were enrolled and randomly allocated into a control group and an observation group. The control group received triptorelin plus mifepristone, while the observation group was additionally treated with HYXZD. Both groups were treated for 3 months. Clinical efficacy was compared, and the following parameters were measured before and after treatment: menstrual flow, fibroid volume, sex hormone levels (LH, E<sub>2</sub>, FSH), uterine artery hemodynamics (PI, RI, S/D), hemorheologic parameters (BVH/BVL, PAGT), serum tumor markers (CA125, CEA), adverse reactions, and 1-year recurrence rate. The total effective rate was higher in the observation group relative to the control group (P < 0.05). Before treatment, no notable differences existed between groups in menstrual flow, fibroid volume, LH, E<sub>2</sub>, FSH, PI, RI, S/D, BVH, BVL, PAGT, CA125, or CEA (P > 0.05). Following treatment, both groups showed reductions in menstrual flow, fibroid volume, LH, E<sub>2</sub>, FSH, BVH, BVL, PAGT, CA125, and CEA, with greater reductions in the observation group (P < 0.05); PI, RI, and S/D increased in both groups, with better improvements in the observation group (P < 0.05). The adverse reaction rate was lower in the observation group versus the control group (P = 0.013). At the 1-year follow up, recurrence occurred in 11.76% (6/51) of patients in the control group and 7.84% (4/51) of patients in the observation group (P = 0.505). HYXZD combined with triptorelin and mifepristone improves clinical outcomes in uterine fibroid treatment by reducing fibroid size, optimizing hormone levels and hemodynamics, lowering tumor markers, and maintaining safety.
Study Information
pubmed
2025
2025-10-23T00:00:00.000Z
10.1002/ijgo.70601
33